dzd6008
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2024 (NCT06813365)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07079475 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2025 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT07070440 | Phase 1/Phase 2 (Phase 2) | Jul 16, 2025 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Jiao Tong University |
| NCT06905197 | Phase 1 | May 13, 2025 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT06813365 | Phase 1 | Jun 12, 2024 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | For profit | 4 | 4 | 2 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1